Cellcept Oral & IV 250 mg. 1.5g. 1g Capsules. Powder for Oral Suspension. Infusion (Parenteral). Tablets
PDF Leaflet Revision Date: 23 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prophylaxis of organ rejection in transplant patients.
Dosage (summary)
Adults: 1 g orally or IV twice daily; max 2 g/day for renal; 1.5 g for cardiac.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; teratogenic effects reported.
Key Drug Interactions
- Acyclovir
- Antacids
- Cholestyramine
- Ciclosporin A
- Rifampicin
Contraindications
- Pregnancy
- Lactation
- Hypersensitivity to mycophenolate
- Contraceptive non-compliance
Common side effects
- Diarrhoea
- Leucopenia
- Sepsis
- Vomiting
Counselling Points
- Use effective contraception
- Report signs of infection
- Avoid live vaccines
Serious warnings
- Increased risk of infections and malignancies
- Teratogenic effects
- Neutropenia monitoring required
Important Disclaimer
The Cellcept Oral & IV 250 mg. 1.5g. 1g Capsules. Powder for Oral Suspension. Infusion (Parenteral). Tablets professional information leaflet below is the property of Roche and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
